• 作者：L. Morell^a ; ^{laiamorell@hotmail.com} ; J.M. Carrascosa^a ; C. Ferrá ; ndiz^a ; M. Garcí ; a-Bustinduy^b ; E. Fonseca^c ; G. Carretero^d ; E. Daudé ; n^e ; S.E. Marró ; n^f ; J.L. Ló ; pez-Estebaranz^g ; M. Ferrá ; n^h ; M. Sá ; nchez-Regañ ; aⁱ ; C. Muñ ; oz-Santos^j ; I. Belinchó ; n^k ; Luis Puig^l ; Grupo Espa&ntilde ; ol de Psoriasis
• 关键词：Efalizumab ; EMEA ; Rebote ; Exacerbació ; n inflamatoria generalizada
• 刊名：Actas Dermo-Sifiliogr谩ficas
• 出版年：2011
• 期刊代码：pca35_00017310
• 类别：med
• 出版时间：June 2011
• 卷：102
• 期：5
• 页码：354-364
• 文件大小：396 K

Background and objectives

The withdrawal of marketing authorization for efalizumab by the European Medicines Agency in February, 2009 provided a unique opportunity to assess the course of disease in patients who were not subject to the selection criteria and biases that were common in the pivotal trials. The aim of this study was to evaluate the course of psoriasis following forced suspension of efalizumab in a group of patients treated in normal clinical practice. As secondary objectives, we sought to assess the relationships between clinical characteristics, treatment response, and disease course during efalizumab treatment and 12 and 24 weeks after suspension.

Patients and methods

Information on the epidemiological profile and disease course during treatment and following suspension of the drug was collected from a group of patients treated with efalizumab. Statistical analyses were performed to identify predictive factors.

Results

One hundred forty-seven patients from 12 Spanish hospitals were included in the study. During treatment, 4%of patients were diagnosed with generalized inflammatory flares. Most patients could be classified as having a good (55%) or moderate (18%) response to treatment. Rebound following withdrawal of efalizumab was observed in 30%of patients. The likelihood of rebound was independent of clinical characteristics, treatment response, or therapeutic approach used by the dermatologist following suspension.

Conclusions

There was a high frequency of rebound following suspension of efalizumab, exceeding the rate reported in pivotal trials. This is particularly noteworthy given the large proportion of patients with a good response to treatment and therefore believed to have a better prognosis. Other significant findings were the higher frequency of positive treatment response than observed in previous studies (possibly influenced by the mean treatment duration) and the high frequency of generalized inflammatory flares.